These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28593508)

  • 41. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
    Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
    Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
    Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
    Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
    Yao W; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
    Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
    Trabucco SE; Gerstein RM; Evens AM; Bradner JE; Shultz LD; Greiner DL; Zhang H
    Clin Cancer Res; 2015 Jan; 21(1):113-22. PubMed ID: 25009295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
    Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
    Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
    Aird F; Kandela I; Mantis C;
    Elife; 2017 Jan; 6():. PubMed ID: 28100400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.
    Baker EK; Taylor S; Gupte A; Sharp PP; Walia M; Walsh NC; Zannettino AC; Chalk AM; Burns CJ; Walkley CR
    Sci Rep; 2015 May; 5():10120. PubMed ID: 25944566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis.
    Wang J; Zhou F; Li Z; Mei H; Wang Y; Ma H; Shi L; Huang A; Zhang T; Lin Z; Wu G
    Sci Rep; 2018 Jan; 8(1):998. PubMed ID: 29343723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment.
    Marchesi I; Fais M; Fiorentino FP; Bordoni V; Sanna L; Zoroddu S; Bagella L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
    Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
    Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma.
    Lee S; Rellinger EJ; Kim KW; Craig BT; Romain CV; Qiao J; Chung DH
    Surgery; 2015 Sep; 158(3):819-26. PubMed ID: 26067464
    [TBL] [Abstract][Full Text] [Related]  

  • 56. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
    Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
    Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
    Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.